Haemophilia
OnlineEarly

doi:10.1111/j.1365-2516.2004.00885.x CASE REPORT

Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency
W. Y. Tcheng, J. Donkin, S. Konzal and W.-Y. Wong

Summary. Use of recombinant factor VIIa (rFVIIa, NovoSeven®) in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half-life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII-deficient adolescent.

__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email